379 related articles for article (PubMed ID: 22233579)
21. Cellular mechanisms involved in protection against influenza virus infection in transgenic mice expressing a TCR receptor specific for class II hemagglutinin peptide in CD4+ and CD8+ T cells.
Bot A; Casares S; Bot S; von Boehmer H; Bona C
J Immunol; 1998 May; 160(9):4500-7. PubMed ID: 9574556
[TBL] [Abstract][Full Text] [Related]
22. CD8 T cell tolerance to a tumor-associated self-antigen is reversed by CD4 T cells engineered to express the same T cell receptor.
Ghorashian S; Veliça P; Chua I; McNicol AM; Carpenter B; Holler A; Nicholson E; Ahmadi M; Zech M; Xue SA; Uckert W; Morris E; Chakraverty R; Stauss HJ
J Immunol; 2015 Feb; 194(3):1080-9. PubMed ID: 25539815
[TBL] [Abstract][Full Text] [Related]
23. Antagonist peptide selects thymocytes expressing a class II major histocompatibility complex-restricted T cell receptor into the CD8 lineage.
Volkmann A; Barthlott T; Weiss S; Frank R; Stockinger B
J Exp Med; 1998 Sep; 188(6):1083-9. PubMed ID: 9743527
[TBL] [Abstract][Full Text] [Related]
24. The development and functions of CD4(+) T cells expressing a transgenic TCR specific for an MHC-I-restricted tumor antigenic epitope.
Han X; Ye P; Luo L; Zheng L; Liu Y; Chen L; Wang S
Cell Mol Immunol; 2011 Jul; 8(4):333-40. PubMed ID: 21643003
[TBL] [Abstract][Full Text] [Related]
25. CD8 T cells, like CD4 T cells, are triggered by multivalent engagement of TCRs by MHC-peptide ligands but not by monovalent engagement.
Stone JD; Stern LJ
J Immunol; 2006 Feb; 176(3):1498-505. PubMed ID: 16424178
[TBL] [Abstract][Full Text] [Related]
26. Soluble peptide-MHC monomers cause activation of CD8+ T cells through transfer of the peptide to T cell MHC molecules.
Ge Q; Stone JD; Thompson MT; Cochran JR; Rushe M; Eisen HN; Chen J; Stern LJ
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13729-34. PubMed ID: 12374859
[TBL] [Abstract][Full Text] [Related]
27. Survival and homeostatic proliferation of naive peripheral CD4+ T cells in the absence of self peptide:MHC complexes.
Clarke SR; Rudensky AY
J Immunol; 2000 Sep; 165(5):2458-64. PubMed ID: 10946271
[TBL] [Abstract][Full Text] [Related]
28. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
29. Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression.
Poncette L; Chen X; Lorenz FK; Blankenstein T
J Clin Invest; 2019 Jan; 129(1):324-335. PubMed ID: 30530988
[TBL] [Abstract][Full Text] [Related]
30. Force-Regulated In Situ TCR-Peptide-Bound MHC Class II Kinetics Determine Functions of CD4+ T Cells.
Hong J; Persaud SP; Horvath S; Allen PM; Evavold BD; Zhu C
J Immunol; 2015 Oct; 195(8):3557-64. PubMed ID: 26336148
[TBL] [Abstract][Full Text] [Related]
31. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.
Ray S; Chhabra A; Chakraborty NG; Hegde U; Dorsky DI; Chodon T; von Euw E; Comin-Anduix B; Koya RC; Ribas A; Economou JS; Rosenberg SA; Mukherji B;
Clin Immunol; 2010 Sep; 136(3):338-47. PubMed ID: 20547105
[TBL] [Abstract][Full Text] [Related]
32. Ikaros null mice display defects in T cell selection and CD4 versus CD8 lineage decisions.
Urban JA; Winandy S
J Immunol; 2004 Oct; 173(7):4470-8. PubMed ID: 15383578
[TBL] [Abstract][Full Text] [Related]
33. Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.
Berdien B; Reinhard H; Meyer S; Spöck S; Kröger N; Atanackovic D; Fehse B
Hum Vaccin Immunother; 2013 Jun; 9(6):1205-16. PubMed ID: 23428899
[TBL] [Abstract][Full Text] [Related]
34. A novel T cell receptor single-chain signaling complex mediates antigen-specific T cell activity and tumor control.
Stone JD; Harris DT; Soto CM; Chervin AS; Aggen DH; Roy EJ; Kranz DM
Cancer Immunol Immunother; 2014 Nov; 63(11):1163-76. PubMed ID: 25082071
[TBL] [Abstract][Full Text] [Related]
35. T-cell Receptors Engineered
Sharma P; Harris DT; Stone JD; Kranz DM
Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
[TBL] [Abstract][Full Text] [Related]
36. Contribution of TCR signaling strength to CD8+ T cell peripheral tolerance mechanisms.
Smith TR; Verdeil G; Marquardt K; Sherman LA
J Immunol; 2014 Oct; 193(7):3409-16. PubMed ID: 25156361
[TBL] [Abstract][Full Text] [Related]
37. The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1.
Jiang H; Chess L
Annu Rev Immunol; 2000; 18():185-216. PubMed ID: 10837057
[TBL] [Abstract][Full Text] [Related]
38. Restricted MHC-peptide repertoire predisposes to autoimmunity.
Logunova NN; Viret C; Pobezinsky LA; Miller SA; Kazansky DB; Sundberg JP; Chervonsky AV
J Exp Med; 2005 Jul; 202(1):73-84. PubMed ID: 15998789
[TBL] [Abstract][Full Text] [Related]
39. A critical role of T cell antigen receptor-transduced MHC class I-restricted helper T cells in tumor protection.
Morris EC; Tsallios A; Bendle GM; Xue SA; Stauss HJ
Proc Natl Acad Sci U S A; 2005 May; 102(22):7934-9. PubMed ID: 15908507
[TBL] [Abstract][Full Text] [Related]
40. Naturally occurring low affinity peptide/MHC class I ligands can mediate negative selection and T cell activation.
Motyka B; Teh HS
J Immunol; 1998 Jan; 160(1):77-86. PubMed ID: 9551958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
